#bscm #divitum #breastoncology @onclive

We are excited about the strong DiviTum TKa results recently published in JCO Precision Oncology!

The study highlights the potential of longitudinal TKa monitoring in MBC and early BC to support treatment decisions.
Read more:: https://loom.ly/Wd6gNxY

#bscm #divitum #breastoncology #rosswellpark

Paolo Tarantino Ranked 38 Worldwide in Breast Oncology by ScholarGPS - OncoDaily Paolo Tarantino Ranked 38 Worldwide in Breast Oncology by ScholarGPS / cancer, OncoDaily, Oncology, Paolo Tarantino

Paolo Tarantino Ranked 38th Worldwide in Breast Oncology by ScholarGPS

@ptarantinomd.bsky.social

oncodaily.com/voices/paolo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastOncology #BreastCancer #ScholarGPS

Just in! 📢 FT permanent #generalsurgery vacancy at
#HumberRiverHealth #TorontoOntario. Application deadline: July31 or until filled. #SurgeonJob #SurgeonJobs #breastsurgery #breastoncology Details: rebrand.ly/x0g7kfj

Paolo Tarantino: The highly awaited Breast Cancer trials with positive results - OncoDaily Paolo Tarantino: The highly awaited Breast Cancer trials with positive results / breast oncology, cancer, ESMO23, fight against cancer, Global fight against

The highly awaited Breast Cancer trials with positive results - Paolo Tarantino
@ptarantinomd.bsky.social
@sabcs.bsky.social

oncodaily.com/blog/208123

#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health

Molecular portraits of human breast tumours - PubMed Human breast tumours are diverse in their natural history and in their responsiveness to treatments. Variation in transcriptional programs accounts for much of the biological diversity of human cells ...

Gene Expression Profiling Leading to Molecular Subtypes of Breast Cancer:

Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications.

#MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology

pubmed.ncbi.nlm.nih.gov/10963602/

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors - PubMed We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary node...

The Tamoxifen Trial.

Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols.

pubmed.ncbi.nlm.nih.gov/2644532/

#BreastCancer #BreastOncology #Pathology #PathSky

Sara Tolaney: HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy - OncoDaily Sara Tolaney: HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy / breast oncology, cancer, chemotherapy, Dana-Farber Cancer

HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy - Sara Tolaney

@danafarber.bsky.social
@stolaney1.bsky.social

oncodaily.com/blog/sara-to...

#BreastOncology #Cancer #Chemotherapy #Oncology #DanaFarberCancerInstitute #FightAgainstCancer #HER3DXd #OncoDaily